Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment-Reference-Cited by-同舟云学术

Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment

Published:2024-05-20 Issue:8 Volume:35 Page:1431-1440
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Moreno-Rabié Catalina^ORCID,Fontenele Rocharles Cavalcante^ORCID,Oliveira-Santos Nicolly^ORCID,Nogueira-Reis Fernanda^ORCID,Van den Wyngaert Tim^ORCID,Jacobs Reinhilde^ORCID

Funder

Karolinska Institute

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00198-024-07108-2.pdf

Reference32 articles.

1. WHO Scientific Group on the Prevention and Management of Osteoporosis (2003) Prevention and management of osteoporosis: report of a WHO scientific group. World Health Organization. In: https://iris.who.int/handle/10665/42841. Accessed 27 Apr 2024

2. Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg 72:1938–1956. https://doi.org/10.1016/j.joms.2014.04.031

3. Aljohani S, Fliefel R, Ihbe J et al (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Cranio-Maxillofac Surg 45:1493–1502. https://doi.org/10.1016/j.jcms.2017.05.028

4. Ruggiero SL, Dodson TB, Aghaloo T et al (2022) American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 80:920–943. https://doi.org/10.1016/j.joms.2022.02.008

5. European Medicines Agency (2022) Aclasta (zoledronic acid). Product information. 09/11/2022 Aclasta - EMEA/H/C/000595 - T/0079. In: https://www.ema.europa.eu/en/documents/product-information/aclasta-epar-product-information_en.pdf. https://www.ema.europa.eu/en/medicines/human/EPAR/aclasta. Accessed 5 Dec 2022